Chimerix Inc

$2.51 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Chimerix Inc

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The Company's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.

Stock Analysis

last close $2.44
1-mo return 9.9%
3-mo return -37.4%
avg daily vol. 8.12M
52-week high 7.42
52-week low 1.27
market cap. $234M
forward pe 1.4
annual div. -
roe -110.9%
ltg forecast -
dividend yield -
annual rev. $1M
inst own. 70.2%

Subscribe now for daily local and international financial news